Next Article in Journal
Regulation and Sensing of Inflammasomes and Their Impact on Intestinal Health
Next Article in Special Issue
In Vivo Imaging of Prostate Cancer Tumors and Metastasis Using Non-Specific Fluorescent Nanoparticles in Mice
Previous Article in Journal
Fibrin-Enhanced Canonical Wnt Signaling Directs Plasminogen Expression in Cementoblasts
Previous Article in Special Issue
Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle

Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, 67100 L’Aquila, Italy
Department of Oncology and Hematology, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy
Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
Department of Radiology, Institute for the Research and Treatment of Cancer, 35128 Padova, Italy
Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(11), 2382;
Received: 1 September 2017 / Revised: 3 November 2017 / Accepted: 7 November 2017 / Published: 9 November 2017
(This article belongs to the Special Issue Chemical and Molecular Approach to Tumor Metastases)
PDF [1037 KB, uploaded 10 November 2017]


Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases. They had received a total of 175 treatments with Melphalan hypoxic perfusion and cytoreductive excision. Among the 41 patients, 22 (53.7%) patients exhibited a wild-type BRAF genotype, 11 of which were not eligible for immunotherapy. The first treatment resulted in a 97.5% response-rate in the full cohort and a 100% response-rate in the 22 wild-type BRAF patients. MST was 18 months in the full sample, 20 months for the 22 wild-type BRAF patients and 21 months for the 11 wild-type BRAF patients not eligible for immunotherapy. Melphalan hypoxic perfusion is a potentially effective treatment for patients with pelvic melanoma loco regional metastases that requires confirmation in a larger multicenter study. View Full-Text
Keywords: melanoma; BRAF; Melphalan; pelvic perfusion; hypoxia; stopflow melanoma; BRAF; Melphalan; pelvic perfusion; hypoxia; stopflow

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Guadagni, S.; Fiorentini, G.; Clementi, M.; Palumbo, G.; Palumbo, P.; Chiominto, A.; Baldoni, S.; Masedu, F.; Valenti, M.; Tommaso, A.D.; Fabi, B.; Aliberti, C.; Sarti, D.; Guadagni, V.; Pellegrini, C. Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma? Int. J. Mol. Sci. 2017, 18, 2382.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top